share_log

Pfizer | SC TO-I/A: Third party tender offer statement (Amendment)

Pfizer | SC TO-I/A: Third party tender offer statement (Amendment)

辉瑞 | SC TO-I/A：发行招标公告
美股SEC公告 ·  09/13 16:52

Moomoo AI 已提取核心信息

Pfizer Inc. has successfully completed its tender offer to modify eligible Performance Share Awards (PSAs) and Total Shareholder Return Units (TSRUs) as detailed in Amendment No. 2 to the Tender Offer Statement on Schedule TO. The offer, which was filed with the Securities and Exchange Commission (SEC), expired on September 12, 2024, at 11:59 p.m. Eastern Time. Following the expiration, Pfizer accepted for modification a total of 1,359,772 Eligible PSAs and 30,360,402 Eligible TSRUs. The modified awards are now subject to the terms and conditions of the 2019 Plan and the applicable award agreements. The vesting and other terms of the Modified PSAs and Modified TSRUs are described in the Schedule TO and the Modification Offer. This final amendment was filed to report the results of the tender offer and to satisfy the disclosure requirements of Rule 13e-4(c)(4) under the Securities Exchange Act of 1934.
Pfizer Inc. has successfully completed its tender offer to modify eligible Performance Share Awards (PSAs) and Total Shareholder Return Units (TSRUs) as detailed in Amendment No. 2 to the Tender Offer Statement on Schedule TO. The offer, which was filed with the Securities and Exchange Commission (SEC), expired on September 12, 2024, at 11:59 p.m. Eastern Time. Following the expiration, Pfizer accepted for modification a total of 1,359,772 Eligible PSAs and 30,360,402 Eligible TSRUs. The modified awards are now subject to the terms and conditions of the 2019 Plan and the applicable award agreements. The vesting and other terms of the Modified PSAs and Modified TSRUs are described in the Schedule TO and the Modification Offer. This final amendment was filed to report the results of the tender offer and to satisfy the disclosure requirements of Rule 13e-4(c)(4) under the Securities Exchange Act of 1934.
辉瑞公司已成功完成其要约收购，以修改符合条件的绩效股票奖励（PSA）和总股东回报单位（TSRU），详见《关于要约收购声明修正案2号的修正案》。该收购要约已提交给美国证监会（SEC），截止时间为2024年9月12日晚上11:59（东部时间）。收购截止后，辉瑞公司接受对1,359,772份符合条件的PSA和30,360,402份符合条件的TSRU进行修改。修改后的奖励现受2019年计划和适用的奖励协议的条款和条件约束。修改后的PSA和TSRU的归属和其他条款详见《要约收购声明修正案》和《修改要约》。此最终修正案报告了要约收购的结果，并满足《1934年证券交易法》第13e-4(c)(4)条下的披露要求。
辉瑞公司已成功完成其要约收购，以修改符合条件的绩效股票奖励（PSA）和总股东回报单位（TSRU），详见《关于要约收购声明修正案2号的修正案》。该收购要约已提交给美国证监会（SEC），截止时间为2024年9月12日晚上11:59（东部时间）。收购截止后，辉瑞公司接受对1,359,772份符合条件的PSA和30,360,402份符合条件的TSRU进行修改。修改后的奖励现受2019年计划和适用的奖励协议的条款和条件约束。修改后的PSA和TSRU的归属和其他条款详见《要约收购声明修正案》和《修改要约》。此最终修正案报告了要约收购的结果，并满足《1934年证券交易法》第13e-4(c)(4)条下的披露要求。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    渤健公司
    BIIB
    -- 151.310
    Organon & Co
    OGN
    -- 15.060
    赛诺菲安万特
    SNY
    -- 48.730
    辉瑞
    PFE
    -- 26.620
    诺华制药
    NVS
    -- 98.390

    解锁榜首股票